IL-12 as an adjuvant for Bordetella pertussis vaccines

Details IL-12 as an adjuvant for Bordetella pertussis vaccines IL-12 as an adjuvant for Bordetella pertussis vaccines

2005-08-16

2005-08-16

Navarro, Mark (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S234100, C424S253100, C424S254100, C424S278100

Reexamination Certificate

active

06929794

ABSTRACT:
This invention provides a composition of at least oneBordetellaantigen and an effective adjuvant amount of interleukin-12 (IL-12), and uses thereof as a vaccine againstBordetellainfection. Methods for using IL-12 as an adjuvant in combination with vaccines againstBordetellaare also provided.

REFERENCES:
patent: 4518584 (1985-05-01), Mark et al.
patent: 4705686 (1987-11-01), Scott et al.
patent: 5427788 (1995-06-01), Rappuoli et al.
patent: 5444159 (1995-08-01), Jackson et al.
patent: 5571515 (1996-11-01), Scott et al.
patent: 5723127 (1998-03-01), Scott et al.
patent: 0 441 900 (1991-08-01), None
patent: 01 193231 (1989-08-01), None
patent: WO 90/05147 (1990-05-01), None
patent: WO 91/01143 (1991-02-01), None
patent: WO 94/01139 (1994-01-01), None
patent: WO 96/01272 (1996-01-01), None
patent: WO 96/10423 (1996-04-01), None
patent: WO 96/11019 (1996-04-01), None
patent: WO 96/40267 (1996-12-01), None
patent: WO 97/00321 (1997-01-01), None
Markoff et al. Bio/Technology 8: 1030-1033, 1990.
Petersen et al. Vaccine 11(4):463-472, 1993.
Redhead et al (Infection & Immunity vol. 61, No. 8. pp 3190-3198), Aug. 1993.
Scott P., “IL-12 Initiation Cytokine for Cell-Mediated Immunity”Science, 260:496-497 (1993).
McDowell R. S. et al., J Amer Chem Soc 114:9245-9253 (1992).
Cohen J., Science 259:1691-1692 (1993).
Fynan E. et al., PNAS USA 90:11478-11482 (1993).
Wolff J. A. et al., Biotechniques 11:474-485 (1991).
Mahon B. P. et al., J Exp Med 181:1285-1292 (1995).
Sato et al., Infect Immun 29:261-266 (1980).
Ryan et al., Immunology 83 Supp 1:34 Abstract 5.7 (1994).
Mills, K. G. H., NIH Meeting Abstract (1996).
Ad Hoc Group for the Study of Pertussis Vaccines, Lancet 1 (8592): 955-60 (1988).
Afonso et al., Science 263: 235-237 (1994).
Bannatyne and Jackowski, Vaccine 5: 268-269 (1987).
Greco et al., N Engl J Med 334(6): 341-348 (1996).
Gustafsson et al., N Engl J Med 334(6): 349-355 (1996).
Miller et al., J Immunol. 115: 4817-4828 (1995).
Ryan et al., Dev Biol Stand 89: 297-305 (1997).
Schijns et al., J. Immunol 155: 2525-2532 (1995).
Sidey et al., Vaccine 7: 237-241 (1989).
Skeen et al., J Immunol 156: 1196-1206 (1996).
Mahon et al., Infect Immun 64: 5295-5301 (1996).
Bliss J. et al., J Immunol 156:887-894 (1996).
McKnight A. J. et al., J Immunol 152:2172-2179 (1994).
Seder R. A. et al., PNAS USA 90:10188-10192 (1993).
Morris S. C. et al., J Immunol 152:1047-1056 (1994).
Flynn J. L. et al., J Immunol 62:2515-2524 (1995).
Gazzinelli R. T. et al., PNAS USA 90:6115-6119 (1993).
Heinzel F. P. et al., J Exp Med 177:1505-1509 (1993).
Hunter C. A. et al., Infect Immun 62:2818-2824 (1994).
Sypek J. P. et al., J Exp Med 177:1797-1802 (1993).
Tripp C. S. et al., J Immunol 152:1883-1887 (1994).
Urban J. F. et al., J Immunol 156:263-268 (1996).
Wynn T. A. et al., J Exp Med 179:1551-1561 (1994).
Zhan Y. et al., Infect Immun 63:1387-1390 (1995).
Renauld-Mongenie G. et al., PNAS USA 93:7944-7949 (1996).
Steffen P. et al., EMBO J 15:102-109 (1996).
Kobayashi M. et al., J Exp Med 170:827 (1989).
Saragovi H. U. et al., Bio/Technology 10:773-778 (1992).
Hausman S. Z. et al., Infect Immun 64:4020-4026 (1996).
LeBlay K. et al., Microbiology 142:971-978 (1996).
Robinson A. et al., Vaccine 3:11-22 (1985).
Friedman R. L. et al., Infect Immun 60:4578-4585 (1992).
Saukkonen K. et al., J Exp Med 173:1143-1149 (1991).
Mills K. H. G. et al., J Med Microbiol 39:163-164 (1993).
Peppoloni S. et al., Infect Immun 59:3768-3773 (1991).
Peterson J. P. et al., Infect Immun.60:4563-4570 (1992).
Mosmann T. R. et al., Adv Immunol 46:111-147 (1989).
Mills K. H. G. et al., Infect Immun 61:399-410 (1993).
Redhead K. et al., Infect Immun 61:3190-3198 (1993).
Barnard A. et al., Immunol 87:372-380 (1996).
Gajewski T. F. et al., J Immunol 146:1750-1758 (1991).
O'Garra A. et al., Curr Opin Immunol 6:458-466 (1994).
Hsieh C. S. et al., Science 260:547-549 (1993).
Trinchieri G., Annu Rev Immunol 13:251-276 (1995).

Affiliated with

Also associated with

Rating

IL-12 as an adjuvant for Bordetella pertussis vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with IL-12 as an adjuvant for Bordetella pertussis vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL-12 as an adjuvant for Bordetella pertussis vaccines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3501422